Lynda Roman

发表

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Molly Brewer, Beth Y Karlan, Daniela Matei, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.